Wells Fargo
STLN

Wells Fargo’s Starling Oncology STLN Stock Holding History

Wells Fargo’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
78,510
+38,087
+94% +$160K ﹤0.01% 4735
2026
Q1 		$124K Sell
40,423
-43,178
-52% -$132K ﹤0.01% 4985
2025
Q4 		$298K Buy
83,601
+45,234
+118% +$168K ﹤0.01% 4842
2025
Q3 		$134K Buy
38,367
+7,863
+26% +$26.9K ﹤0.01% 5161
2025
Q2 		$62.5K Buy
+30,504
New +$76.3K ﹤0.01% 5431
2024
Q2 		– Sell
-248
Closed -$392 – 7462
2024
Q1 		$392 Buy
248
+4
+2% +$8 ﹤0.01% 6333
2023
Q4 		$498 Buy
244
+15
+7% +$26 ﹤0.01% 6382
2023
Q3 		$321 Buy
229
+44
+24% +$46 ﹤0.01% 6460
2023
Q2 		$102 Sell
185
-6,673
-97% -$3.53K ﹤0.01% 6858
2023
Q1 		$4.65K Buy
+6,858
New +$8.75K ﹤0.01% 6072
2022
Q4 		– Sell
-568
Closed -$3K – 7732
2022
Q3 		$3K Buy
568
+98
+21% +$576 ﹤0.01% 6085
2022
Q2 		$2K Buy
470
+406
+634% +$2.96K ﹤0.01% 6381
2022
Q1 		$0 Buy
+64
New +$432 ﹤0.01% 7813

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wells Fargo's STLN Position: Q2 2026 in Review

Wells Fargo increased its Starling Oncology (STLN) stake by 94% in Q2 2026, buying an estimated $160K and bringing the position to 78,510 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #4735.

Wells Fargo first reported a position in STLN in Q1 2022 and has held it in 13 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Wells Fargo held 78,510 shares of Starling Oncology worth $426K as of Q2 2026.
  • Wells Fargo bought 38,087 Starling Oncology shares in Q2 2026, an estimated $160K.
  • Starling Oncology made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4735 holding.
  • Wells Fargo first reported a position in Starling Oncology in Q1 2022 and has held it in 13 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.